Impairment of p38 MAPK-mediated cytosolic phospholipase A2 activation in the kidneys is associated with pathogenicity of Candida albicans

Immunology

Volumn 120, Issue 2, 2007, Pages 173-181

  Choi, Jung Hwa ^a   Choi, Eun Kyoung ^a   Park, Sung Jun ^a   Ko, Hyun Mi ^a,c   Kim, Kyoung Jin ^a   Han, Su Ji ^b   Choi, Il Whan ^d   Im, Suhn Young ^a  

^a Chonnam National University   (South Korea)

^b Pusan National University   (South Korea)

^c Chonbuk National University Medical School   (South Korea)

^d Inje University College of Medicine   (South Korea)

Author keywords

Candida albicans; Mitogen activated protein kinase; Nuclear factor B; Phospholipase A2; Tumour necrosis factor

Indexed keywords

2 [N (2 METHOXY 3 OCTADECYLCARBAMOYLOXYPROPOXYCARBONYL)ACETAMIDOMETHYL] 1 ETHYLPYRIDINIUM CHLORIDE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; AACOCF 3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 INHIBITOR; THROMBOCYTE ACTIVATING FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; KIDNEY; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; CANDIDA ALBICANS; CANDIDIASIS; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION; KIDNEY DISEASES; MICE; MICE, INBRED BALB C; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHOLIPASES A; PHOSPHORYLATION; PLATELET ACTIVATING FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA; VIRULENCE;

EID: 33846028750     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2006.02489.x     Document Type: Article

References (41)

1. Bodey GP. Candidiasis in cancer patients. Am J Med 1984; 77:13-19.
2. Klein RS, Harris CA, Small CB, Moll B, Lesser M, Friedland GH. Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome. N Engl J Med 1984; 311:354-8.
3. Parker JCJ, McCloskey JJ, Solanki KV, Goodman NL. Candidosis: the most common postmortem cerebral mycosis in an endemic fungal area. Surg Neurol 1976; 6:123-8.
4. Cutler JE. Putative virulence factors of Candida albicans. Annu Rev Microbiol 1991; 45:187-218.
5. Matthews RC. Pathogenicity determinants of Candida albicans: potential targets for immunotherapy? Microbiology 1994; 140:1505-11.
6. Odds FC. Pathogenesis of Candida infections. J Am Acad Dermatol 1994; 31:S2-5.
7. Perfect JR. Fungal virulence genes as targets for antifungal chemotherapy. Antimicrob Agents Chemother 1996; 40:1577-83.
8. Braquet P, Touqui L, Shen TY, Vargaftig BB. Perspectives in platelet-activating factor research. Pharmacol Rev 1987; 39:97-145.
9. Shukla SD. Platelet-activating factor receptor and signal transduction mechanisms. FASEB J 1992; 6:2296-301.
10. Buttke TM, Sandstrom PA. Redox regulation of programmed cell death in lymphocytes. Free Radic Res 1995; 22:389-97.
11. Fukuda AI, Breuel KF. Effect of platelet activating factor on embryonic development and implantation in the mouse. Hum Reprod 1996; 11:2746-9.
12. Im SY, Choi JH, Ko HM, Han SJ, Chun SB, Lee HG, HATY. A protective role of platelet-activating factor in murine candidiasis. Infect Immun 1997; 65:1321-6.
13. Choi JH, Ko HM, Kim JW, Lee HK, Han SS, Chun SB, Im SY. Platelet-activating factor-induced early activation of NF-κB plays a crucial role for organ clearance of Candida albicans. J Immunol 2001; 166:5139-44.
14. Touqui L, Jacquemin C, Dumarey C, Vargaftig BB. 1-O-alkyl-2-acyl- sn-glycero-3-phosphorylcholine is the precursor of platelet-activating factor in stimulated rabbit platelets. Evidence for an alkylacetyl- glycerophosphorylcholine cycle. Biochim Biophys Acta 1985; 833:111-18.
15. 2 enzymes: regulation and physiological role. Biochem Pharmacol 1994; 48:1-10.
16. Gomez-Cambronero J, Nieto ML, Mato JM, Sanchez-Crespo M. Modulation of lyso-platelet-activating factor: acetyl-CoA acetyltransferase from rat splenic microsomes. The role of calcium ions. Biochim Biophys Acta 1985; 845:511-15.
17. 2 is a 100-kDa protein in human monoblast U937 cells. J Biol Chem 1991; 266:5268-72.
18. 2. J Biol Chem 1997; 272:16709-12.
19. 2 enzymes: classification and characterization. Biochim Biophys Acta 2000; 1488:1-19.
20. 2: structure and function. Biochim Biophys Acta 2000; 1488:28-39.
21. 2 enzymes. Prostaglandins Other Lipid Med 2002; 68-69:3-58.
22. 2 from the human monocytic cell line U937. Proc Natl Acad Sci USA 1990; 87:7708-12.
23. 2. J Biol Chem 1991; 226:14850-3.
24. Kobayashi I, Kondoh Y, Shimizu K, Tanaka K. A role of secreted proteinase of Candida albicans for the invasion of chick chorioallantoic membrane. Microbiol Immunol 1989; 33:709-19.
25. Im SY, Han SJ, Ko HM et al. Involvement of nuclear factor-κB in platelet-activating factor-mediated tumor necrosis factor-α expression. Eur J Immunol 1997; 27:2800-4.
26. Han SJ, Choi JH, Ko HM et al. Glucocorticoids prevent NF-κB activation by inhibiting the early release of platelet-activating factor in response to LPS. Eur J Immunol 1999; 29:1334-41.
27. Han SJ, Ko HM, Choi JH et al. Molecular mechanisms for lipopolysaccharide-induced biphasic activation of nuclear factor-κB (NF-κB). J Biol Chem 2002; 277:44715-21.
28. 2. Br J Pharmacol 2005; 144:940-52.
29. 2 is phosphorylated and activated by MAP kinase. Cell 1993; 72:269-78.
30. 2. J Biol Chem 1994; 269:19480-7.
31. 2 regulation. J Biol Chem 2000; 275:20146-56.
32. Ko HM, Seo KH, Han SJ et al. NF-κB-dependency of platelet-activating factor-induced angiogenesis. Cancer Res 2002; 62:1809-14.
33. Baeuerle PA, Baltimore D. Activation of DNA-binding activity in an apparently cytoplasmic precursor of the NF-κB transcription factor. Cell 1988; 53:211-17.
34. Kopp E, Ghosh S. NF-κB and Rel proteins in innate immunity. Adv Immunol 1995; 58:1-27.
35. Van't Wout JW, Van der Meer JW, Barza M, Dinarello CA. Protection of neutropenic mice from lethal Candida albicans infection by recombinant interleukin 1. Eur J Immunol 1988; 18:1143-6.
36. Louie A, Baltch AL, Smith RP et al. Tumor necrosis factor alpha has a protective role in a murine model of systemic candidiasis. Infect Immun 1994; 62:2761-72.
37. Kullberg BJ, Netea MG, Curfs JH, Keuter M, Meis JF, van der Meer JW. Recombinant murine granulocyte colony-stimulating factor protects against acute disseminated Candida albicans infection in nonneutropenic mice. J Infect Dis 1998; 177:175-81.
38. Netea MG, Van Der Graaf CA, Vonk AG, Verschueren I, Van Der Meer JW, Kullberg BJ. The role of toll-like receptor (TLR) 2 and TLR4 in the host defense against disseminated candidiasis. J Infect Dis 2002; 185:1483-9.
39. Roeder A, Kirschning CJ, Rupec RA, Schaller M, Weindl G, Korting HC. Toll-like receptors as key mediators in innate antifungal immunity. Med Mycol 2004; 42:485-98.
40. Bellocchio S, Montagnoli C, Bozza S et al. The contribution of the Toll-like/IL-1 receptor superfamily to innate and adaptive immunity to fungal pathogens in vivo. J Immunol 2004; 172:3059-69.
41. Heinsbroek SE, Brown GD, Gordon S. Dectin-1 escape by fungal dimorphism. Trends Immunol 2005; 26:352-4.